# Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Canonical URL: https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-strengthens-financial-leadership-with-appointment-of-ryan-maynard-as-chief-financial-officer
Ticker: FHTX
Company: Foghorn Therapeutics
Source: Foghorn Therapeutics
Published: 2026-02-23 12:00 EST
Original Source URL: https://ir.foghorntx.com
## Summary

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as

## Article Body
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as
## Recent Company News
- 2026-05-12 11:00 EST — [Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may) — Source: Foghorn Therapeutics
- 2026-05-07 11:00 EST — [Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-first-quarter-2026-financial-and-corporate-update) — Source: Foghorn Therapeutics
- 2026-04-21 20:05 EST — [Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting) — Source: Foghorn Therapeutics
- 2026-04-09 11:00 EST — [Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting) — Source: Foghorn Therapeutics
- 2026-03-11 20:10 EST — [Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-financial-update-for-2025-and-2026-strategic-outlook) — Source: Foghorn Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)